Skip to main content
Premium Trial:

Request an Annual Quote

Zycos Wins DNA-Delivery Patent

NEW YORK, Nov. 19 — Zycos, a Lexington, Mass., drug-development company, announced on Monday that it has been granted a patent on its microparticle DNA delivery method.


According to the company, the invention, called GENCAP, protects DNA from degradation in the body. The microparticles that protect the DNA are derived from a material also used in resorbable sutures, and Zycos has adapted the material to encapsulate and protect plasmid DNA vaccines.


This technique, according to the company, is superior to naked DNA vaccines in its ability to deliver antigen-coding DNA into relevant immune system cells and generate a robust B-cell and cytotoxic T-cell response.


The patent was granted on Oct. 30.


Zycos is also developing its own drug pipeline, focusing on treatments for cancers, infectious diseases and autoimmune disorders, and currently has one treatment for cervical dysplasia in early clinical trials.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.